Literature DB >> 22154675

Antimicrobial resistance of Moraxella catarrhalis isolates in Taiwan.

Shih-Fen Hsu1, Yi-Tsung Lin, Te-Li Chen, L K Siu, Po-Ren Hsueh, Shih-Tse Huang, Chang-Phone Fung.   

Abstract

BACKGROUND/
PURPOSE: The prevalence of ampicillin-resistant Moraxella catarrhalis has been higher in Taiwan than in other countries, with reports of 97.7% in the 1990s. The aims of this study were to assess resistance trends for M. catarrhalis, which causes respiratory tract infections, against several classes of oral antibiotics and to compare the minimum inhibitory concentration (MIC) of antimicrobial agents against M. catarrhalis isolates between 1993-1994 and 2001-2004.
METHODS: Clinical isolates of M. catarrhalis (n = 314) were collected from 11 large medical centers in Taiwan between 2001 and 2004. β-Lactamase production tests were performed. The MICs for 13 different oral antibiotics were calculated using the agar dilution method. Pulsed-field gel electrophoresis (PFGE) was performed for 18 randomly selected high-level ampicillin-resistant (BRO-1 β-lactamase-positive, MIC ≥ 32 μg/mL) isolates to investigate their genetic relatedness.
RESULTS: The overall rate of β-lactamase-producing isolates was 97.8% (307/314). All isolates were susceptible to amoxicillin + clavulanate, chloramphenicol, cefixime, ciprofloxacin, erythromycin, levofloxacin, moxifloxacin, and roxithromycin. The rate of resistance to cefaclor and cefuroxime was 8.3% and 1.3%, respectively, while no resistance was found in 1993-1994. Resistance to trimethoprim-sulfamethoxazole (SXT) and tetracycline was 18.5% and 19.8%, respectively. Comparison of 1993-1994 and 2001-2004 isolates revealed that the zone diameter for amoxicillin + clavulanate disks decreased from 43 mm in 1993-1994 to 32 mm in 2001-2004 (p < 0.001). However, MIC(50) (0.25 μg/mL in both 1993-1994 and 2001-2004) and MIC(90) (0.5 μg/mL in both 1993-1994 and 2001-2004) for amoxicillin + clavulanate did not differ between the study periods. The PFGE typing results demonstrate that at least two closely related BRO-1 clones are spreading in Taiwan.
CONCLUSION: The rates of resistance to cefaclor, cefuroxime, tetracycline and SXT are now increasing in Taiwan. Molecular typing showed that at least two closely related BRO-1 clones are circulating. Although amoxicillin + clavulanate remains the antimicrobial therapy of choice for M. catarrhalis infections, continued surveillance of antimicrobial susceptibility and application of control measures against further transmission are required to inhibit the emergence of the resistant strains.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154675     DOI: 10.1016/j.jmii.2011.09.004

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  9 in total

1.  Antimicrobial susceptibility of bacterial isolates from patients presenting with ear, nose and throat (ENT) infections in the German community healthcare setting.

Authors:  B Olzowy; M Kresken; M Havel; D Hafner; B Körber-Irrgang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-20       Impact factor: 3.267

2.  RNA-Seq-based analysis of the physiologic cold shock-induced changes in Moraxella catarrhalis gene expression.

Authors:  Violeta Spaniol; Stefan Wyder; Christoph Aebi
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

3.  Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant Moraxella catarrhalis strains isolated in Poland.

Authors:  Katarzyna Król-Turmińska; Alina Olender
Journal:  Infect Drug Resist       Date:  2018-08-06       Impact factor: 4.003

4.  Nasal Resistome Development in Infants With Cystic Fibrosis in the First Year of Life.

Authors:  Aurélie Allemann; Julia G Kraemer; Insa Korten; Kathryn Ramsey; Carmen Casaulta; Daniel Wüthrich; Alban Ramette; Andrea Endimiani; Philipp Latzin; Markus Hilty
Journal:  Front Microbiol       Date:  2019-02-26       Impact factor: 5.640

5.  In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis.

Authors:  Xiang Sun; Bo Zhang; Guangjian Xu; Junwen Chen; Yongpeng Shang; Zhiwei Lin; Zhijian Yu; Jinxin Zheng; Bing Bai
Journal:  Ann Lab Med       Date:  2021-05-01       Impact factor: 3.464

6.  Prevalence of Moraxella Catarrhalis as a Nasal Flora among Healthy Kindergarten Children in Bhaktapur, Nepal.

Authors:  Neetu Amatya; Govinda Paudel; Bhuvan Saud; Sunita Wagle; Vikram Shrestha; Bibhav Adhikari
Journal:  Interdiscip Perspect Infect Dis       Date:  2022-03-26

7.  Development of a multiplex real-time PCR assay for the simultaneous detection of four bacterial pathogens causing pneumonia.

Authors:  Ho Jae Lim; Eun-Rim Kang; Min Young Park; Bo Kyung Kim; Min Jin Kim; Sunkyung Jung; Kyoung Ho Roh; Nackmoon Sung; Jae-Hyun Yang; Min-Woo Lee; Sun-Hwa Lee; Yong-Jin Yang
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

8.  Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections.

Authors:  Safia Bader Uddin Shaikh; Zafar Ahmed; Syed Ali Arsalan; Sana Shafiq
Journal:  Infect Drug Resist       Date:  2015-07-31       Impact factor: 4.003

9.  Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents.

Authors:  Tamara Bandet; Sue Whitehead; Edith Blondel-Hill; Ken Wagner; Naowarat Cheeptham
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-05       Impact factor: 2.471

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.